<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00949247</url>
  </required_header>
  <id_info>
    <org_study_id>CASE4108</org_study_id>
    <nct_id>NCT00949247</nct_id>
  </id_info>
  <brief_title>Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases</brief_title>
  <official_title>Docetaxel, Carboplatin, Trastuzumab and Bevacizumab (TCH+B) For Early-Stage HER-2/Neu(+) Breast Cancer and Bone Marrow Micrometastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Monoclonal antibodies, such as trastuzumab and bevacizumab, can block tumor growth&#xD;
      in different ways. Some block the ability of tumor cells to grow and spread. Others find&#xD;
      tumor cells and help kill them or carry tumor-killing substances to them. Giving chemotherapy&#xD;
      together with monoclonal antibody therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how well giving docetaxel and carboplatin together&#xD;
      with trastuzumab and bevacizumab works in treating patients with stage I, stage II, or stage&#xD;
      III breast cancer and bone marrow micrometastases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the clinical response in patients with HER2/neu-positive stage I-III breast&#xD;
           cancer and bone marrow micrometastases treated with docetaxel, carboplatin, trastuzumab,&#xD;
           and bevacizumab.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Investigate the specific contribution of VEGF and CXCL-12 (SDF-1) signaling to bone&#xD;
           marrow support of HER2/neu-positive breast cancer cells.&#xD;
&#xD;
        -  Evaluate growth factor and chemokine expression profiles to investigate the potential&#xD;
           correlation of expression with patient outcome and frequency of tumor cell clusters&#xD;
           (mammospheres with tumor stem cell phenotype) in microenvironment supported cultures.&#xD;
&#xD;
      OUTLINE: Patients receive docetaxel IV, carboplatin IV, and bevacizumab IV over 30-90 minutes&#xD;
      on day 1 and trastuzumab IV over 30-90 minutes on days 1, 8, and 15. Treatment repeats every&#xD;
      21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6&#xD;
      courses, treatment modifications may apply according to response.&#xD;
&#xD;
      Tumor tissue and bone marrow samples may be collected for further laboratory analysis.&#xD;
&#xD;
      After completion of study therapy, patients are followed up for 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who have a complete response in bone marrow.</measure>
    <time_frame>at 4 weeks after completing 6 courses of therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Specific contribution of VEGF and CXCL-12 (SDF-1) signaling to bone marrow support of HER2/neu-positive breast cancer cells</measure>
    <time_frame>pre- and post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential correlation of growth factor and chemokine expression with patient outcome and frequency of tumor cell clusters (mammospheres with tumor stem cell phenotype) in microenvironment supported cultures</measure>
    <time_frame>pre- and post-therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel,Carboplatin,Trastuzumab and Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.</description>
    <arm_group_label>Docetaxel,Carboplatin,Trastuzumab and Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <description>Trastuzumab IV over 30-90 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.</description>
    <arm_group_label>Docetaxel,Carboplatin,Trastuzumab and Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Carboplatin IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.</description>
    <arm_group_label>Docetaxel,Carboplatin,Trastuzumab and Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>Docetaxel IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.</description>
    <arm_group_label>Docetaxel,Carboplatin,Trastuzumab and Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Tumor tissue and bone marrow samples may be collected for further laboratory analysis.</description>
    <arm_group_label>Docetaxel,Carboplatin,Trastuzumab and Bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Patient with biopsy-proven primary stage I-III infiltrating adenocarcinoma of the&#xD;
             breast.&#xD;
&#xD;
          -  HER-2/neu (+) as determined by either IHC (3+) or FISH (≥ 2.2-fold amplification).&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  ECOG performance status 0-1.&#xD;
&#xD;
          -  Negative CT C/A/P and TBBS.&#xD;
&#xD;
          -  LVEF &gt; 50% by MUGA or echocardiogram performed within 28 days prior to enrollment&#xD;
&#xD;
          -  Positive BM aspirate for BC micrometastases by CLIA-certified laboratory.&#xD;
&#xD;
          -  Adequate hematologic, hepatic, and renal function. All tests must be obtained ≤ 4&#xD;
             weeks prior to randomization.&#xD;
&#xD;
               -  Hematologic: Absolute neutrophil count &gt; 1,500/mm3 Hemoglobin &gt; 10.0 g/dl&#xD;
                  Platelet count &gt; 100,000/mm3.&#xD;
&#xD;
               -  Hepatic: Total bilirubin must be within normal limits. Transaminases (AST and/or&#xD;
                  ALT) may be &lt; 2.5 x institutional upper limit of normal (ULN) if alkaline&#xD;
                  phosphatase is &lt; ULN, or alkaline phosphatase may be &lt; 4 x ULN if transaminases&#xD;
                  are &lt; ULN&#xD;
&#xD;
               -  Renal: Normal creatinine and BUN; if abnormal, calculated creatinine clearance&#xD;
                  must be&gt; 60 mg/dL&#xD;
&#xD;
          -  Patients must be disease-free of prior invasive malignancies for ≥ 5 years, with the&#xD;
             exception of curatively-treated basal cell or squamous cell carcinoma of the skin or&#xD;
             carcinoma in situ of the cervix.&#xD;
&#xD;
          -  Surgery: all patients must have completed surgery with sentinel and/or axillary lymph&#xD;
             node dissection according to participating institutional guidelines.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative pregnancy test and must be&#xD;
             willing to consent to using an accepted and effective barrier form method of&#xD;
             contraception while on treatment and for a reasonable period thereafter.&#xD;
&#xD;
          -  Patients must provide written informed consent.&#xD;
&#xD;
          -  Note: Hormonal therapy: patients with ER+ and/or PR+ tumors may receive concurrent&#xD;
             hormonal therapy according to participating institutional guidelines. The choice of&#xD;
             hormonal therapy is at the discretion of the treating physician.&#xD;
&#xD;
          -  Note: Radiation therapy: patients receiving adjuvant radiation therapy to the involved&#xD;
             breast (after partial mastectomy) or chest wall (after mastectomy) may receive&#xD;
             concurrent trastuzumab and bevacizumab therapy.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Known metastatic BC.&#xD;
&#xD;
          -  Concomitant malignancies or previous malignancies within the last 5 years, with the&#xD;
             exception of adequately treated basal or squamous cell carcinoma of the skin or&#xD;
             carcinoma in situ of the cervix.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Prior chemotherapy, hormonal therapy, trastuzumab and bevacizumab therapy.&#xD;
&#xD;
          -  History of significant cardiac disease, cardiac risk factors or uncontrolled&#xD;
             arrhythmias&#xD;
&#xD;
          -  Ejection fraction &lt;50% or below the lower limit of the institutional normal range,&#xD;
             whichever is lower.&#xD;
&#xD;
          -  Hypersensitivity to trial medications.&#xD;
&#xD;
          -  Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs,&#xD;
             resulting in dyspnea at rest.&#xD;
&#xD;
          -  Active or uncontrolled infection.&#xD;
&#xD;
          -  Psychiatric, addictive, or any disorder that compromises the ability to give informed&#xD;
             consent to participate in or to comply with the requirements of the study.&#xD;
&#xD;
        Bevacizumab-Specific Exclusions&#xD;
&#xD;
          -  Inadequately controlled hypertension (defined as systolic blood pressure &gt;150 and/or&#xD;
             diastolic blood pressure &gt; 100 mmHg on antihypertensive medications)&#xD;
&#xD;
          -  Any prior history of hypertensive crisis or hypertensive encephalopathy&#xD;
&#xD;
          -  New York Heart Association (NYHA) Grade II or greater congestive heart failure&#xD;
&#xD;
          -  History of stroke or transient ischemic attack within 6 months prior to study&#xD;
             enrollment&#xD;
&#xD;
          -  Known CNS disease&#xD;
&#xD;
          -  Significant vascular disease (e.g., aortic aneurysm, aortic dissection)&#xD;
&#xD;
          -  Symptomatic peripheral vascular disease&#xD;
&#xD;
          -  Evidence of bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days&#xD;
             prior to study enrollment or anticipation of need for major surgical procedure during&#xD;
             the course of the study&#xD;
&#xD;
          -  Core biopsy or other minor surgical procedure, excluding placement of a vascular&#xD;
             access device, within 7 days prior to study enrollment&#xD;
&#xD;
          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess&#xD;
             within 6 months prior to study enrollment&#xD;
&#xD;
          -  Serious, non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  Proteinuria at screening as demonstrated by either&#xD;
&#xD;
          -  Urine protein:creatinine (UPC) ratio &gt;/= 1.0 at screening OR&#xD;
&#xD;
          -  Urine dipstick for proteinuria ≥ 2+ (patients discovered to have ≥2+ proteinuria on&#xD;
             dipstick urinalysis at baseline should undergo a 24 hour urine collection and must&#xD;
             demonstrate ≤ 1g of protein in 24 hours to be eligible).&#xD;
&#xD;
          -  Known hypersensitivity to any component of bevacizumab&#xD;
&#xD;
          -  Pregnant (positive pregnancy test) or lactating. Use of effective means of&#xD;
             contraception (men and women) in subjects of child-bearing potential&#xD;
&#xD;
          -  History of stroke or transient ischemic attack at any time&#xD;
&#xD;
          -  History of myocardial infarction or unstable angina within 12 months of study&#xD;
             enrollment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Baar, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Budd, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Monarch</name>
      <address>
        <city>Mayfield Heights</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Chagrin Highlands Medical Center</name>
      <address>
        <city>Orange Village</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Westlake</name>
      <address>
        <city>Westlake</city>
        <state>Ohio</state>
        <zip>44145</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 29, 2009</study_first_submitted>
  <study_first_submitted_qc>July 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2009</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>HER2-positive breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Micrometastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

